Richter’s Transformation in Chronic Lymphocytic Leukemia

Richter’s transformation is the sudden shift of chronic lymphocytic leukemia, a slow-growing blood cancer, into a fast-moving aggressive lymphoma. It happens in roughly 2 to 10 percent of people with CLL, and when it does, the outlook changes dramatically: survival is often measured in months rather than years.¹ The transformation usually takes the form of diffuse large B-cell lymphoma, though a small fraction becomes Hodgkin lymphoma instead. Understanding what triggers this switch, who faces the highest risk, and what newer treatments can offer is an area of intense research and, for patients living with CLL, a source of real anxiety.

How Often Does It Happen, and When

The often-cited figure of 2 to 10 percent captures a wide range because study populations, follow-up lengths, and diagnostic methods vary. A Danish nationwide study tracking nearly 3,800 CLL patients over a median follow-up of about four years found a five-year cumulative incidence of 2.8 percent, with biopsy-confirmed transformation in 113 patients.² The annual incidence rate sits around half a percent to one percent per year of living with CLL.³ Transformation can show up before a person has ever been treated for CLL, but it is more common after one or more rounds of therapy. There is no set timeline: some patients transform within months of their CLL diagnosis, others after a decade or more.

Who Is Most at Risk

Not every CLL patient carries the same odds of transformation, and researchers have identified a handful of features at the time of CLL diagnosis that raise or lower the risk. Two large analyses point to several overlapping factors. In a multicenter study, independent predictors of transformation included advanced disease stage, the chromosome abnormality del(17p), and unmutated immunoglobulin heavy chain variable region genes, a marker that already signals more aggressive CLL behavior.⁴ An earlier Italian study found that large lymph nodes (3 centimeters or bigger) at diagnosis, CD38 expression on the leukemia cells, and the absence of del(13q14) were the strongest independent predictors, with bulky lymph nodes carrying the highest risk.⁵

One striking finding from that same study is that the risk factors for transformation are not the same as the risk factors for ordinary CLL progression. In other words, what makes CLL advance slowly is not necessarily what tips it into a completely different disease. This distinction matters clinically because patients who look “stable” by one set of criteria could still be accumulating molecular damage that nudges the disease toward transformation.

Warning Signs and How Transformation Is Detected

When CLL transforms, the clinical picture usually changes fast. Patients often develop rapidly enlarging lymph nodes, unexplained fevers, drenching night sweats, and sharp drops in weight. Rising lactate dehydrogenase levels in the blood are a classic laboratory hint, though not specific to transformation on their own. The difficulty is that CLL itself can flare up and cause some of these symptoms, so distinguishing a flare from full transformation requires more than blood work.

PET/CT scanning has become the primary tool for raising suspicion. The idea is straightforward: transformed lymphoma tissue is far more metabolically active than indolent CLL tissue and therefore lights up much brighter on a PET scan. A widely used threshold is a peak uptake value above 5, which in one early study yielded a sensitivity of about 91 percent and a specificity of 80 percent for detecting transformation.⁶ A larger meta-analysis covering 10 studies confirmed that moderate thresholds in that range give pooled sensitivity near 90 percent but lower specificity, around 54 percent, meaning that some hot spots on PET turn out not to be transformation. Raising the threshold to a peak value of 9 or 10 improves specificity to about 84 percent at the cost of missing some cases.⁷

Because PET alone cannot confirm the diagnosis, a tissue biopsy of the suspicious node remains essential. Under the microscope, the vast majority of transformation cases show an immunoblastic morphology, and the tumor cells commonly express markers like CD5, MUM1, and LEF1, which help pathologists distinguish them from ordinary large B-cell lymphomas that arise without a CLL history.⁸ About 78 percent of cases fall into the non-germinal center B-cell subtype, a category that in the de novo setting already tends to carry a worse prognosis.

What Drives the Transformation

Most Richter transformations are “clonally related,” meaning the aggressive lymphoma evolved directly from the original CLL clone rather than arising as a brand-new cancer. Clonally related cases carry a worse outlook than the minority of unrelated cases.⁹ Interestingly, even the supposedly “unrelated” cases are not exactly identical to ordinary large B-cell lymphoma that appears in someone who never had CLL. Genetic sequencing shows that these unrelated cases carry mutations in TP53, MYC, ATM, and NOTCH1, genes more characteristic of clonally related transformation, while lacking many of the mutations typical of truly de novo lymphoma.¹⁰ This suggests that having CLL in the background somehow shapes the genetic landscape even of “new” lymphomas that appear.

Three molecular events stand out as transformation drivers. TP53 disruption, through mutations or chromosome deletions, removes a critical brake on cell growth and explains why transformed disease is so resistant to chemotherapy. MYC activation, achieved either by chromosomal rearrangements that move MYC next to a strong promoter or by NOTCH1 mutations that crank up MYC signaling indirectly, pushes cells toward rapid proliferation. Loss of the CDKN2A gene, which normally helps regulate the cell cycle, compounds the effect.¹¹ In one genomic analysis, recurrent MYC abnormalities correlated with MYC overexpression in over half of cases, and some tumors achieved MYC overexpression through mutations in the MYC promoter region rather than through structural rearrangements.¹²

The Hodgkin Lymphoma Variant

While the vast majority of Richter transformations become diffuse large B-cell lymphoma, a small subset takes on the features of classical Hodgkin lymphoma instead. This variant is uncommon enough that large series are rare, and most of what we know comes from retrospective reviews. In a study of 77 cases, the Hodgkin-type cells were positive for Epstein-Barr virus about 71 percent of the time, which is a much higher rate than in ordinary Hodgkin lymphoma, suggesting that EBV-driven reactivation in the setting of CLL-related immune suppression plays a key role.¹³

Pathologists recognize two patterns in CLL patients: isolated Hodgkin-type cells sitting within the CLL tissue itself, and full-blown classical Hodgkin lymphoma. The first pattern sometimes progresses into the second. Overall median survival after diagnosis of either pattern was about 44 months in that cohort, which is considerably longer than what is typically seen with the DLBCL form of transformation. Age, rather than which pattern was present, was the major factor driving survival differences. The prognosis of the Hodgkin variant is generally considered better than the DLBCL type, though it remains a serious diagnosis with limited evidence to guide treatment choices.¹⁴

Why Standard Chemotherapy Falls Short

The regimen used as a first-line treatment for ordinary diffuse large B-cell lymphoma, known as R-CHOP, cures a majority of patients with that de novo disease. In transformation, the results are far grimmer. In a single-center experience of 204 patients with Richter transformation, those treated with R-CHOP or similar regimens had a median overall survival of about 15 months. Switching to more aggressive platinum-based or high-dose chemotherapy did not improve on that: median survival was essentially the same.¹⁵ The near-universal presence of TP53 abnormalities in transformed disease largely explains this resistance, since TP53 is the gene that allows chemotherapy to trigger cell death.

For patients who do respond to initial chemotherapy well enough to qualify, allogeneic stem cell transplant from a donor offers the best shot at durable remission. A single-center analysis found that long-term overall survival was expected in 41 to 75 percent of patients who entered transplant with an objective response to treatment.¹⁶ The catch is that most patients never make it to transplant, either because their disease does not respond well enough to initial treatment, because they are too unwell to tolerate the procedure, or because a suitable donor cannot be found in time.¹⁷ This therapeutic bottleneck has been one of the strongest motivations for developing newer immunotherapy approaches.

Bispecific Antibodies and CAR T-Cell Therapy

Two classes of immunotherapy have generated the most interest in Richter transformation over the past few years. Bispecific antibodies are engineered proteins that grab onto both a tumor cell and a T cell at the same time, essentially forcing the immune system to attack. In clinical trials, several of these drugs have shown meaningful activity. Glofitamab, in a small cohort of 11 patients with relapsed or refractory transformation, achieved an overall response rate of about 64 percent, with roughly 46 percent reaching complete response. Mosunetuzumab showed a 40 percent response rate in 20 patients.¹⁸ Epcoritamab, given subcutaneously, produced an overall response rate of about 48 percent at a median follow-up of nearly 23 months, with responses appearing somewhat better in patients receiving it as first-line treatment for their transformation than in those who had already failed prior therapy.¹⁹

CAR T-cell therapy, in which a patient’s own T cells are genetically modified to recognize and kill cancer cells, has also shown encouraging early results. A European multicenter retrospective analysis of 54 patients treated with anti-CD19 CAR T cells reported an overall response rate of 65 percent, with about half achieving complete response by three months. Median progression-free survival was 8 months and median overall survival was roughly 14 months.²⁰ A smaller series of eight patients found that five of the seven responders achieved complete response by day 28. Cytokine release syndrome, the most common side effect, occurred in most patients but was manageable with standard supportive care, and there were no treatment-related deaths.²¹

These numbers are genuinely better than what has historically been achievable with chemotherapy alone, though the patient populations are small and follow-up periods are still short. Whether bispecific antibodies or CAR T cells will ultimately prove superior to each other, or to chemotherapy followed by transplant in eligible patients, remains an open question.

Transformation During Modern CLL Treatments

Targeted therapies like ibrutinib (a BTK inhibitor) and venetoclax (a BCL-2 inhibitor) have transformed the treatment of CLL itself, but they have not eliminated the risk of Richter transformation. When transformation occurs in patients on these drugs, the biology can look somewhat different. In a molecular analysis of six patients who transformed while on ibrutinib or venetoclax, all carried TP53 abnormalities. Two of five ibrutinib-treated patients had developed a specific resistance mutation in the BTK gene, and one venetoclax-treated patient had acquired a BCL-2 mutation associated with drug resistance.²² Rare histologic subtypes were also observed, including plasmablastic lymphoma, a particularly aggressive form that almost never arises in the traditional chemoimmunotherapy setting.

Whether modern targeted therapies change the overall rate of transformation, rather than just which patients transform and what it looks like when they do, is still debated. Some registry data suggest the rate has not moved much. What is clearer is that patients whose CLL breaks through a targeted agent are a self-selected high-risk group, and their transformations tend to be driven by multiple layers of resistance mutations stacked on top of the usual molecular damage.

The Immune Microenvironment and Checkpoint Molecules

Beyond the tumor cells themselves, the surrounding immune environment in Richter transformation is measurably different from both CLL and ordinary lymphoma. A study comparing PD-1 expression found that the T cells infiltrating transformation-type DLBCL expressed PD-1 at far higher rates than those in de novo DLBCL: 9 out of 11 transformation cases versus only 5 out of 47 de novo cases.²³ PD-1 on T cells is one of the brakes the tumor uses to suppress the immune response. High PD-1 expression in transformation suggests that the immune system is being actively held in check, which has fueled interest in checkpoint inhibitor therapy for these patients.

However, the picture is not as simple as just releasing the brakes. In the same study, the tumor cells themselves in transformation cases did not express PD-L1, the binding partner for PD-1. Instead, PD-L1 was found on histiocytes and dendritic cells in the background tissue. This means that the classic model of tumor cells using PD-L1 to directly shield themselves does not neatly apply here. The immune suppression in Richter transformation appears to involve a more complex interplay among the tumor, the immune cells, and the surrounding tissue. Clinical trials of checkpoint inhibitors in Richter transformation have shown mixed results, consistent with this complicated biology.

Central Nervous System Involvement

One feared complication that does not get enough attention is the spread of transformed disease into the central nervous system. This is rare even among Richter transformation patients, but when it happens, it poses distinct treatment challenges because many drugs do not cross the blood-brain barrier effectively. A Mayo Clinic review assembled a cohort of 26 patients with CNS involvement by Richter transformation, which underscores just how uncommon this is, but also that it does occur and requires a specific management approach.²⁴ Patients with CNS involvement may present with headaches, confusion, cranial nerve deficits, or vision changes layered on top of the systemic symptoms of their transformation. Recognizing these neurologic red flags early is important because treatment decisions, including whether intrathecal chemotherapy or CNS-penetrant drugs are needed, depend on catching the diagnosis promptly.

Living with the Risk

For the large majority of CLL patients who will never transform, the existence of Richter’s transformation can still cast a long shadow. Some patients develop significant anxiety about every new symptom or rising blood count. It helps to keep perspective on the numbers: even in the higher estimates, roughly 90 percent of CLL patients will not experience transformation. At the same time, dismissing the risk entirely is not wise. Paying attention to sudden changes matters: rapid lymph node growth, new fevers or night sweats, unexplained weight loss, or a sharp rise in lactate dehydrogenase should prompt a conversation with a hematologist and, when appropriate, PET imaging and biopsy.

Because prognosis after transformation is so much worse than in CLL itself, there is a real argument for aggressive monitoring in patients with known high-risk features, particularly unmutated immunoglobulin genes, del(17p), bulky lymph nodes, or TP53 mutations. These patients may benefit from being seen at centers with experience managing transformation, where rapid access to clinical trials, bispecific antibodies, CAR T-cell programs, and transplant evaluation is available. The pace of change in treatment options has been faster in the last five years than in the previous several decades, and staying connected to a treatment center that offers newer therapies can meaningfully affect outcomes.